Your browser doesn't support javascript.
loading
Effects of subcutaneous and intravenous golimumab on inflammatory biomarkers in patients with rheumatoid arthritis: results of a phase 1, randomized, open-label trial.
Doyle, Mittie K; Rahman, Mahboob U; Frederick, Bart; Birbara, Charles A; de Vries, Dick; Toedter, Gary; Wu, Xiaoying; Chen, Dion; Ranganath, Veena K; Westerman, Mark E; Furst, Daniel E.
Affiliation
  • Doyle MK; Janssen Research & Development, LLC, Spring House, PA, USA. doylem@alxn.com
Rheumatology (Oxford) ; 52(7): 1214-9, 2013 Jul.
Article in En | MEDLINE | ID: mdl-23418046
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Biomarkers / Tumor Necrosis Factor-alpha / Antibodies, Monoclonal Type of study: Clinical_trials / Systematic_reviews Limits: Adult / Humans Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2013 Document type: Article Affiliation country: Country of publication:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Arthritis, Rheumatoid / Biomarkers / Tumor Necrosis Factor-alpha / Antibodies, Monoclonal Type of study: Clinical_trials / Systematic_reviews Limits: Adult / Humans Language: En Journal: Rheumatology (Oxford) Journal subject: REUMATOLOGIA Year: 2013 Document type: Article Affiliation country: Country of publication: